Nanopharm

Nanopharm_logo

Nanopharm, an Aptar company, provides integrated development services in materials characterisation, formulation development and inhaled biopharmaceutics for tailored analytical and drug development, with a focus on orally inhaled and nasal drug products.

Associated Companies

Aptar Pharma Aptar Digital Health Gateway Analytical Next Breath Nanopharm

Headquarters
Nanopharm Ltd, an Aptar Company
Imperial House
Imperial Way
Coedkernew, Newport
NP10 8UH
United Kingdom

Phone / Contact

T: +44 1633 504 776
E: [email protected]

Connect

Nanopharm provides tailored analytical and drug development services, with a focus on orally inhaled and nasal drug products. The company’s unique processing technologies and formulation development tools enable translation of preclinical development through to clinical manufacturing.

Nanopharm’s integrated development services in materials characterisation, formulation development and inhaled biopharmaceutics aid successful product development by enabling its client to understand how material properties and processing conditions influence product functionality.

In June 2019, the company was acquired by Aptar Pharma.

Articles by Nanopharm

ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS

Gemma Budd and Julie Suman, consider the key issues that preclinical and clinical trials for orally inhaled and nasal drug products must address within the context of the information that regulators are looking for, providing insight, strategies and advice for both novel and generic products in this sector.

NAVIGATING pMDI REFORMULATION 2.0

Chris Baron and William Ganley examine possible responses to the environmental impact of pressurised metered dose inhalers use and consider alternative inhaler types, with a focus on the strategies and support that can accelerate the development of the next generation of pMDIs.

STEPS TO SUCCESS IN NOSE-TO-BRAIN DRUG DELIVERY

Reenal Gandhi and Gemma Budd consider the multiple hurdles associated with developing nasal drug delivery solutions, current understanding of the associated biology and the advantages of alternative device designs and state-of-the-art formulation practice.

INVESTIGATING THE PROPELLANT PATHWAYS LEADING TO A SUSTAINABLE FUTURE FOR MDIS

Chris Baron and Jag Shur discuss the various dynamics involved in realising the full potential of MDIs to deliver both improved environmental performance and even better patient outcomes.

Dr Robert Price

DEVELOPING AN IN VITRO DISSOLUTION AND RELEASE SYSTEM FOR ORALLY INHALED DRUG PRODUCTS

Robert Price critiques regulatory routes for the development of generic OINDPs, runs through recent announcements and developments of note from regulators, and describes how Nanopharma has pioneered the concept of structural Q3 equivalence.

Aptar Group Releases COVID-19 Update for its Customers and Partners

Aptar Pharma has released a message from its President and Chief Executive Officer to provide a COVID-19 update to inform its customers and partners of the measures the Group is taking in regards to the evolving coronavirus pandemic in order to continue to support our customers.

A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE

Jag Shur explores the challenges companies face in bringing generic respiratory and nasal therapies to market – and how some organisations have proactively addressed the challenge and developed services to integrate the device and the formulation, introducing the Aptar Pharma Services offering.

Top